.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

SIGNIFOR Drug Profile

« Back to Dashboard
Signifor is a drug marketed by Novartis and Novartis Pharms Corp and is included in two NDAs. It is available from one supplier. There are five patents protecting this drug.

This drug has one hundred and sixteen patent family members in thirty-nine countries.

The generic ingredient in SIGNIFOR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.

Summary for Tradename: SIGNIFOR

Patents:5
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: SIGNIFOR

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYes7,759,308► subscribeY ► subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-002Dec 15, 2014RXNo► subscribe► subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYes7,473,761► subscribeYY ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SIGNIFOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 20126,225,284► subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 20126,225,284► subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 20126,225,284► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SIGNIFOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,625Somatostatin analogues► subscribe
9,035,021Somatostatin analogues► subscribe
8,822,637Somatostatin analogues► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SIGNIFOR

Country Document Number Estimated Expiration
Hungary9901455► subscribe
Iceland2705► subscribe
Norway317867► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SIGNIFOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012 00024Denmark► subscribe
0120019 00062Estonia► subscribePRODUCT NAME: SIGNIFOR-PASIREOTIID;REG NO/DATE: C(2012) 2910 FINAL 24.04.2012
C/GB12/030United Kingdom► subscribePRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc